Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

Texas MPN Workshop 2020 | Ruxolitinib in 2020 and beyond

Aaron Gerds • 27 Aug 2020
Texas MPN Workshop 2020
Myeloproliferative Neoplasms Ruxolitinib

Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, discusses the use and impact of ruxolitinib for treating patients with myeloproliferative neoplasms (MPNs). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Aaron Gerds

Practical advice for community physicians managing patients with anemia and myelofibrosis 1:18
Practical advice for community physicians managing patients with anemia and myelofibrosis
Aaron Gerds • 23 Aug 2025
Mechanisms driving anemia in myelofibrosis and approaches under development for this complication 2:11
Mechanisms driving anemia in myelofibrosis and approaches under development for this complication
Aaron Gerds • 23 Aug 2025
The recent updates to the NCCN Guidelines for systemic mastocytosis 1:45
The recent updates to the NCCN Guidelines for systemic mastocytosis
Aaron Gerds • 19 Aug 2024
Ruxolitinib in 2024 and beyond: the good, the suboptimal, and the failure 1:46
Ruxolitinib in 2024 and beyond: the good, the suboptimal, and the failure
Aaron Gerds • 19 Aug 2024

Related Videos

Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach 2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors 1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS 10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
The value of fedratinib for the treatment of patients with MF in the second-line setting 1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals